Loading
Nippon Kayaku
Nippon Kayaku is a Japanese chemicals and pharmaceuticals group whose medicines business specialises in cancer: generic chemotherapy, supportive care products and biosimilars of antibodies such as trastuzumab for the Japanese market.
Also called: Nippon Kayaku Co., Ltd.日本化薬
Overview
Nippon Kayaku, listed in Tokyo, is a diversified chemicals company whose pharmaceutical division concentrates on oncology in Japan, supplying generic cytotoxic drugs, supportive care medicines and biosimilar antibodies including a trastuzumab biosimilar, and running the domestic phase 3 trials that biosimilar approval in Japan requires. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Headquarters
Tokyo, JP
Scorecard
All companies#92of 1245 companies, score 53
- approved products +6
- targets +4
- modalities +4
- regions +7
- 24-month regulatory events +2
- registry trials +30
1 approved, 0 in phase 3, 0 earlier, 2 targets, 1,258 registry studies. Formula on the scorecards page.
Type
Stage
Public
Products
2ApprovedMonoclonal antibody (anti-HER2)
Trastuzumab · Herceptin (and biosimilars, Phesgo with pertuzumab)
The first targeted antibody for a solid tumour (1998), which turned HER2-positive breast cancer from the worst subtype into one of the most treatable.
EstablishedAnthracycline (topoisomerase II inhibitor), intravenous or intravesical
Pirarubicin is a doxorubicin relative developed in Japan and used there and in China for breast cancer, lymphoma, bladder cancer and other tumours, including instillation into the bladder after tumour resection.
Connected
5Similar pages
- CompanyPregLem
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
- CompanyEmergent BioSolutions
- CompanyHarbour BioMed
- CompanyVion Pharmaceuticals
- CompanyCyclacel Pharmaceuticals
fronts
drugs
EstablishedAnthracycline (topoisomerase II inhibitor), intravenous or intravesical
ApprovedMonoclonal antibody (anti-HER2)
Trastuzumab · Herceptin (and biosimilars, Phesgo with pertuzumab)
terms
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
nipponkayaku.co.jp · 1
A source that has moved or gone is reported by the weekly link check. /audit/
ProvenanceLast edited 2026-09-18 · Jude Gomila · Add Wikidata ids and Wikipedia links for 80 more companies · diff · file
Sourced, not expert-reviewed